Edwards lifesciences (ew) faces investor class action lawsuit over tavm platform disclosures, deadline pending – hagens berman

Ew investors with losses encouraged to contact the firm before dec. 13, 2024 deadline san francisco, ca / accesswire / december 11, 2024 / investors in edwards lifesciences corporation (nyse:ew) contend that the medical device giant misled them about the growth prospects of its core product, the transcatheter aortic valve replacement (tavr) platform. a class action lawsuit has been filed, accusing the company of securities fraud and claiming that executives painted a misleading picture of tavr's future growth potential.
EW Ratings Summary
EW Quant Ranking